Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review.
Hum Vaccin Immunother
; 18(5): 2045857, 2022 11 30.
Article
in English
| MEDLINE | ID: covidwho-1730555
ABSTRACT
The U.S. Centers for Disease Control and Prevention (CDC) and other health agencies have recently recommended a booster dose of COVID-19 vaccines for specific vulnerable groups including adults 65 years and older. There is limited evidence whether vaccine effectiveness (VE) in older adults decreases over time, especially against severe COVID-19. We performed a rapid review of published studies available through 4 November 2021 that provide effectiveness data on messenger RNA (mRNA) vaccines approved/licensed in the United States and identified eight eligible studies which evaluated VE in older adults. There is evidence of a decline in VE against both severe acute respiratory syndrome coronavirus 2 infection and severe COVID-19 in older adults among studies which analyzed data up to July-October 2021. Our findings suggest that VE diminishes in older adults, which supports the current recommendation for a booster dose in this population.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Vaccines
/
COVID-19
Type of study:
Experimental Studies
/
Randomized controlled trials
/
Reviews
Topics:
Vaccines
Limits:
Aged
/
Humans
Country/Region as subject:
North America
Language:
English
Journal:
Hum Vaccin Immunother
Year:
2022
Document Type:
Article
Affiliation country:
21645515.2022.2045857
Similar
MEDLINE
...
LILACS
LIS